BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 24402972)

  • 21. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HMGCS2 functions as a tumor suppressor and has a prognostic impact in prostate cancer.
    Wan S; Xi M; Zhao HB; Hua W; Liu YL; Zhou YL; Zhuo YJ; Liu ZZ; Cai ZD; Wan YP; Zhong WD
    Pathol Res Pract; 2019 Aug; 215(8):152464. PubMed ID: 31176575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.
    Roudier MP; Winters BR; Coleman I; Lam HM; Zhang X; Coleman R; Chéry L; True LD; Higano CS; Montgomery B; Lange PH; Snyder LA; Srivastava S; Corey E; Vessella RL; Nelson PS; Üren A; Morrissey C
    Prostate; 2016 Jun; 76(9):810-22. PubMed ID: 26990456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.
    Shiota M; Takeuchi A; Song Y; Yokomizo A; Kashiwagi E; Uchiumi T; Kuroiwa K; Tatsugami K; Fujimoto N; Oda Y; Naito S
    Endocr Relat Cancer; 2011 Aug; 18(4):505-17. PubMed ID: 21652770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dynamin 2 mediates PDGFRα-SHP-2-promoted glioblastoma growth and invasion.
    Feng H; Liu KW; Guo P; Zhang P; Cheng T; McNiven MA; Johnson GR; Hu B; Cheng SY
    Oncogene; 2012 May; 31(21):2691-702. PubMed ID: 21996738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy.
    Geybels MS; Wright JL; Bibikova M; Klotzle B; Fan JB; Zhao S; Feng Z; Ostrander EA; Lin DW; Nelson PS; Stanford JL
    Clin Epigenetics; 2016; 8():97. PubMed ID: 27651837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dysregulation of the splicing machinery is directly associated to aggressiveness of prostate cancer.
    Jiménez-Vacas JM; Herrero-Aguayo V; Montero-Hidalgo AJ; Gómez-Gómez E; Fuentes-Fayos AC; León-González AJ; Sáez-Martínez P; Alors-Pérez E; Pedraza-Arévalo S; González-Serrano T; Reyes O; Martínez-López A; Sánchez-Sánchez R; Ventura S; Yubero-Serrano EM; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
    EBioMedicine; 2020 Jan; 51():102547. PubMed ID: 31902674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
    Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
    Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphodiesterase
    Waldbillig F; Nitschke K; Abdelhadi A; von Hardenberg J; Nuhn P; Nientiedt M; Weis CA; Michel MS; Erben P; Worst TS
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32575490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ARHGAP29 expression may be a novel prognostic factor of cell proliferation and invasion in prostate cancer.
    Shimizu K; Matsumoto H; Hirata H; Ueno K; Samoto M; Mori J; Fujii N; Kawai Y; Inoue R; Yamamoto Y; Yano S; Shimabukuro T; Furutani-Seiki M; Matsuyama H
    Oncol Rep; 2020 Dec; 44(6):2735-2745. PubMed ID: 33125156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of PRL1 as a novel diagnostic and therapeutic target for castration-resistant prostate cancer by the Escherichia coli ampicillin secretion trap (CAST) method.
    Shinmei S; Sentani K; Hayashi T; Sakamoto N; Goto K; Oo HZ; Naito Y; Teishima J; Matsubara A; Oue N; Kuniyasu H; Yasui W
    Urol Oncol; 2014 Aug; 32(6):769-78. PubMed ID: 24968948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The previously uncharacterized lncRNA APP promotes prostate cancer progression by acting as a competing endogenous RNA.
    Shi X; Zhang W; Nian X; Lu X; Li Y; Liu F; Wang F; He B; Zhao L; Zhu Y; Ren S; Sun Y
    Int J Cancer; 2020 Jan; 146(2):475-486. PubMed ID: 31107971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High Expression of KIF22/Kinesin-Like DNA Binding Protein (Kid) as a Poor Prognostic Factor in Prostate Cancer Patients.
    Zhang Z; Xie H; Zhu S; Chen X; Yu J; Shen T; Li X; Shang Z; Niu Y
    Med Sci Monit; 2018 Nov; 24():8190-8197. PubMed ID: 30427826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients.
    Avgeris M; Stravodimos K; Fragoulis EG; Scorilas A
    Br J Cancer; 2013 Jun; 108(12):2573-81. PubMed ID: 23703249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ERG protein expression and gene rearrangements are present at lower rates in metastatic and locally advanced castration-resistant prostate cancer compared to localized disease.
    Teng LH; Wang C; Bégin LR; Dolph M; Yilmaz A; Trpkov K; Donnelly B; Bismar TA
    Urology; 2013 Aug; 82(2):394-9. PubMed ID: 23746715
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ankyrin G expression is associated with androgen receptor stability, invasiveness, and lethal outcome in prostate cancer patients.
    Wang T; Abou-Ouf H; Hegazy SA; Alshalalfa M; Stoletov K; Lewis J; Donnelly B; Bismar TA
    J Mol Med (Berl); 2016 Dec; 94(12):1411-1422. PubMed ID: 27534968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer.
    Darnel AD; Behmoaram E; Vollmer RT; Corcos J; Bijian K; Sircar K; Su J; Jiao J; Alaoui-Jamali MA; Bismar TA
    Clin Cancer Res; 2009 Feb; 15(4):1376-83. PubMed ID: 19228738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.
    Montironi R; Mazzucchelli R; Barbisan F; Stramazzotti D; Santinelli A; Scarpelli M; Lòpez Beltran A
    Hum Pathol; 2006 Sep; 37(9):1137-44. PubMed ID: 16938518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. βKlotho inhibits androgen/androgen receptor‑associated epithelial‑mesenchymal transition in prostate cancer through inactivation of ERK1/2 signaling.
    Liu Z; Zhang H; Ding S; Qi S; Liu S; Sun D; Dong W; Yin L; Li M; Zhao X; Lu J
    Oncol Rep; 2018 Jul; 40(1):217-225. PubMed ID: 29749458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy.
    Guan Y; Wu Y; Liu Y; Ni J; Nong S
    Prostate; 2016 Aug; 76(11):986-93. PubMed ID: 27040772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.